Premium
P4‐388: XANAMEM TM : A Novel 11B‐HSD1 Inhibitor with Potential to Provide Durable Symptomatic and Disease Modifying Benefits in Alzheimer’S Disease
Author(s) -
Ritchie Craig W.,
Webster Scott,
Cummings Jeffrey L.,
Masters Colin L.,
Ruffles Vincent,
Seckl Jonathan,
Walker Brian R.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.07.133
Subject(s) - endocrinology , medicine , metabolite , glucocorticoid , testosterone (patch) , pharmacodynamics , potency , glucocorticoid receptor , chemistry , pharmacokinetics , biochemistry , in vitro
total creatine [NAA/tCr]), membrane turnover (total choline [tCho/ tCr]), and the glial marker myo-inositol (mI/tCr) from HC, ACC, and posterior cingulate cortex. Group differences were analysed using mixed models. Results:PME/PDE was higher after 4 weeks of test product compared to control (LS mean difference1⁄40.18, SEM1⁄40.06, p1⁄40.005). A similar effect was observed for PEth/ GPEth (LS mean difference1⁄40.22, SEM1⁄40.13, p1⁄40.091). Higher total choline after 4 weeks of test product compared to control was observed in the ACC and right hippocampus (LS mean difference1⁄40.04 and 0.02; SEM1⁄40.02 and 0.01; p1⁄40.068 and 0.003, respectively). Significant group differences were found in nutritional blood markers, but not in other MRS measures. Conclusions: The current results suggest enhanced brain phospholipid formation compared to breakdown after 4 weeks intervention with Souvenaid in patients with mild AD. The observed effects indicate that Souvenaid not only raises circulating levels of nutrients and fatty acids, but also affects brain phospholipid metabolism in patients with mild AD, which confirms results from prior animal studies. This supports the hypothesis that Souvenaid enhances the formation of neuronal membranes.